Clinical trial
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent…
NCT03828617 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT03828617 |
|---|---|
| Title | Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults |
| Official title | A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumococcal Disease |
| Intervention type | Biological |
| Interventions | 20vPnC, 13vPnC |
| Enrollment | 1,710 |
| Start date | Feb 14, 2019 |
| Primary completion | Oct 9, 2019 |
| Completion | Oct 9, 2019 |
| First posted | Feb 4, 2019 |
| Last update posted | Nov 23, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: